Orca-Q
Acute Undifferentiated Leukemia
University of FloridaCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
32 Active assets in the Acute Undifferentiated Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
Cytosin-Arabinosid Fred Hutchinson Cancer Center | Phase 3 | BB |
VINCRISTINE SULFATE M.D. Anderson Cancer Center | Phase 3 | BB |
DEXAMETHASONE Therapeutic Advances in Childhood Leukemia Consortium | Phase 3 | BB |
METHOTREXATE Therapeutic Advances in Childhood Leukemia Consortium | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Orca-Q is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
CCC
Indicative ·
48 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →